Q1 2025 Ambu A/S Earnings Call Transcript
Key Points
- Ambu AS (AMBFF) reported a strong start to the financial year with a 19.5% organic revenue growth and an EBIT margin of 16.1%.
- The Endoscopy Solutions segment saw significant growth, with Pulmonology increasing by 17.7% and Urology, ENT, and GI combined growing by 23.9%.
- The company announced the registration of a new airway management solution, SureSight, which is expected to strengthen their leadership in the market.
- Ambu AS (AMBFF) upgraded its financial guidance for the year, now expecting 11% to 14% organic revenue growth and a 13% to 15% EBIT margin.
- The company continues to focus on innovation and portfolio expansion, particularly in Urology with the launch of aScope 5 Uretero and aScope 5 Cysto HD.
- Free cash flow for the quarter was DKK60 million, slightly lower than previous quarters due to increased inventories in preparation for new product launches.
- Despite strong growth, the company noted fluctuations in quarterly growth rates, particularly in the Pulmonology segment, which may not sustain the 17% growth level in future quarters.
- The EBIT margin, while strong, is influenced by currency effects, and there is an expectation of lower offsetting currency effects in the future.
- The company faces competition, particularly in the Urology segment, from lower-priced Chinese players, which could impact pricing strategies.
- There is a cautious outlook on the Anesthesia and Patient Monitoring segment, with potential volume impacts as customers test alternatives due to previous price increases.
/- -
Hello, everyone, and welcome to this call where I, together with my colleague, Henrik Skak Bender, our CFO, I'm Britt Meelby Jensen, the CEO. And together, we will present the Q1 '24-'25 results from Ambu.
Let me start with the key messages from this first quarter, where we had a strong start to our '24-'25 financial year. We continued with very strong organic revenue growth, posting 19.5% growth and also an increase in our profitability with an EBIT margin of 16.1%. Looking at our key focus area, our Endoscopy Solutions, we saw a strong growth in both segments that we report on. Our Pulmonology business grew by 17.7% in the quarter, and we had a growth in Urology, ENT and GI combined of 23.9%.
Also, we continue to be highly focused on innovation, and this is where we were excited to announce the registration of our new airway management solution, SureSight, our video laryngoscopy solution that I'll come back and talk about later in this call.
And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
